DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Phase 1

Completed

Conditions: Castration-resistant Prostate Cancer

Interventions: Drug: Crizotinib
Drug: Enzalutamide

First Posted Date: 2014-08-04

Last Posted Date: 2022-01-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 24

Registration Number: NCT02207504

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Everolimus for Cancer With TSC1 or TSC2 Mutation

Phase 2

Completed

Conditions: TSC1
Tuberous Sclerosis Complex
MTOR
TSC2

Interventions: Drug: Everolimus

First Posted Date: 2014-07-28

Last Posted Date: 2020-09-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT02201212

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD

Phase 2

Completed

Conditions: Graft Versus Host Disease

Interventions: Drug: Natalizumab
Drug: Methylprednisolone

First Posted Date: 2014-06-26

Last Posted Date: 2020-04-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 21

Registration Number: NCT02176031

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases

Early Phase 1

Recruiting

Conditions: Stage I-III Colon Cancer
Stage IV Colon Cancer With Resectable Liver Metastases
Stage, Colon Cancer

Interventions: Drug: Placebo
Drug: Vitamin D3

First Posted Date: 2014-06-24

Last Posted Date: 2024-08-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 80

Registration Number: NCT02172651

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST

Phase 1

Completed

Conditions: Gastrointestinal Stromal Tumor

Interventions: Drug: Sunitinib
Drug: Regorafenib

First Posted Date: 2014-06-16

Last Posted Date: 2021-06-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 14

Registration Number: NCT02164240

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

Phase 1

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: IPI-145
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2014-06-06

Last Posted Date: 2024-11-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 32

Registration Number: NCT02158091

Locations: 🇺🇸
Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

Phase 2

Terminated

Conditions: Invasive Breast Cancer (Stage I-III)
Ductal Carcinoma in Situ
Lobular Carcinoma in Situ
Lobular Carcinoma
Fatigue Related to Cancer Treatment

Interventions: Drug: Naltrexone
Drug: Sugar Pill

First Posted Date: 2014-05-13

Last Posted Date: 2021-11-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 3

Registration Number: NCT02137252

Locations: 🇺🇸
Massachusetts General Hosptial, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Healthy Directions After Lung Surgery Pilot

Not Applicable

Completed

Conditions: Carcinoma, Non Small Cell Lung

Interventions: Behavioral: Lifestyle counseling

First Posted Date: 2014-05-09

Last Posted Date: 2018-07-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 42

Registration Number: NCT02135211

Locations: 🇺🇸
Brigham & Woman's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL

Phase 2

Completed

Conditions: Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia

Interventions: Drug: Idelalisib
Drug: Ofatumumab

First Posted Date: 2014-05-09

Last Posted Date: 2024-10-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 27

Registration Number: NCT02135133

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumor
Metastatic Solid Tumor

Interventions: Drug: carboplatin
Drug: pioglitazone

First Posted Date: 2014-05-08

Last Posted Date: 2016-05-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 28

Registration Number: NCT02133625

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy